您所在的位置: 首页 --> 导师团队 --> 丁宁

导师基本信息

  • 姓名:丁宁
  • 性别:
  • 民族:汉族
  • 科室:淋巴肿瘤内科
  • 职称:副研究员
  • 专业:肿瘤学
  • E-MAIL: ningding@bjmu.edu.cn

学术论文 | 研究方向 | 科研项目

Sun Y#, Ding N#, Song Y#, Yang Z, Liu W*, Zhu J*, Rao Y*. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant Non-Hodgkin lymphomas.,Leukemia,2019;33(8):2105-10.

Sun Y#, Zhao X#, Ding N#, Gao H#, Wu Y, Yang Y, Zhao M, Hwang J, Song Y, Liu W*, Rao Y*. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.,Cell Research,28(7):779-81.

Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N*, Song Y*, Zhu J*. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton’s tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.,Int J Cancer.,142:202-213

Liu Y, Wang X, Deng L, Ping L, Shi Y, Zheng W, Lin N, Wang X, Tu M, Xie Y, Liu W, Ying Z, Zhang C, Pan Z, Wang X, Ding N*, Song Y*, Zhu J*. ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma.,Cancer Cell Int,19:32

Ding H#, Cheng X#, Ding N#, Tian Z, Zhu J, Zhou C, Shen J*, Song Y*. Association between LAPTM4B gene polymorphism and susceptibility to and prognosis of diffuse large B-cell lymphoma.,Oncol Lett,15:264-70.

Ping L#, Ding N#, Shi Y, Feng L, Li J, Liu Y, Lin Y, Shi C, Wang X, Pan Z, Song Y, Zhu J. The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.,Oncotarget.,39218-39229.

PAK1诱导套细胞淋巴瘤发生伊布替尼耐药的分子机制研究, 课题负责人 , 2020.1.1~2023.12.31, 国家自然科学基金

套细胞淋巴瘤发生依鲁替尼耐药的分子作用机制及相关治疗策略研究, 课题负责人 , 2017.1.1~2019.12.31, 北京市自然科学基金

新型Btk抑制剂PLS-123联合用药治疗套细胞淋巴瘤的作用机制研究, 课题负责人 , 2017.1.1~2017.12.31, 国家自然科学基金

社会任职

  • 抗白血病联盟&抗淋巴瘤联盟青年委员会委员